Jason B Litten MD is the Chief Medical Officer of Genelux Corporation, a developer of novel cancer medicines. Dr. Litten is an expert in clinical oncology who has led the development of numerous oncology drugs including therapeutic monoclonal antibodies, orally available small molecules and some of the first engineered cellular therapies.
Prior to Genelux, Dr Litten served as the Chief Medical Officer of Chimeric Therapeutics and before that at Artiva Biotherapeutics where he built and led all clinical translational and regulatory functions. Prior to Artiva, Dr. Litten was the Vice President of Clinical Development overseeing solid tumor programs at Juno Therapeutics, Inc. Before Juno Therapeutics, he was Vice President of Clinical Development at Clovis Oncology, Inc. Dr. Litten started his industry career in Oncology Clinical Development at Amgen Inc.
Dr. Litten holds a B.S. from Cornell University and M.D. from Emory University. After medical school, he completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern. Since leaving academic medicine almost twenty years ago, Dr. Litten has dedicated his career to developing new medicines for cancer patients in the biopharmaceutical field.
